OraSure wins FDA EUA for OraQuick Ebola 2.0 rapid antigen test - OSUR News | RalliesOraSure wins FDA EUA for OraQuick Ebola 2.0 rapid antigen test
O
OSUR• FDA emergency use authorization for OraQuick Ebola 2.0
- OraSure won FDA emergency use authorization for its second-generation OraQuick Ebola 2.0 rapid antigen test.
- The test covers suspected live patients using whole blood, and cadaveric oral fluid; results are available in 30 minutes without instruments.
- BARDA supported development under a 2022 contract, and OraSure is ramping up production amid the Central Africa outbreak.
